Villejuif

• MagnetisMM-6: A Phase 3 Study of Elranatamab (PF-06863135) + Daratumumab + Lenalidomide Versus Daratumumab + Bortezomib + Lenalidomide + Dex … Recruiting
  2024-514139-50-00 5 2022-11-14 Multiple myeloma
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of Glofitamab in Monotherapy and in Combination with Che … Recruiting
  2023-504264-41-00 9 2022-11-04 CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)
• A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors … Recruiting
  2024-514266-39-00 7 2022-11-03 Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors wit
• First-in-Human Study of RLY-2608 in Advanced Breast Cancer and Other Solid Tumors. Recruiting
  2022-500264-35-00 1 2022-10-28 Advanced solid tumor with a PIK3CA mutation in blood and/or tumor per
• CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics Recruiting
  2022-500295-60-00 4 2022-09-15 Acute Myeloid Leukemia
• MetroWilms Recruiting
  2022-502687-20-00 4 2022-09-14 Wilms tumor
• A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple M … Recruiting
  2023-506247-42-00 3 2022-08-17 Relapsed/Refractory Multiple Myeloma
• A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Sele … Recruiting
  2024-512822-28-00 1 2022-08-08 Advanced or metastatic solid tumors
• Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) Recruiting
  2022-502756-31-00 7 2022-07-20 KRAS G12C-Mutant Advanced Solid Tumors
• RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting
  2023-503267-42-00 5 2022-06-10 Patients with a histological diagnosis of mismatch- repair deficient h
• A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/o … Recruiting
  2024-516331-27-00 3 2022-06-10 Participants with BRAF and/or NRAS mutation positive tumors
• Study of axitinib +/- pembrolizumab in first line treatment for patients with locally advanced or metastatic papillary renal cell carcinoma … Recruiting
  2024-513986-38-00 4 2022-06-01 Locally advanced or metastatic papillary cell carcinoma (PRCC)
• Brigatinib in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors (Briga-PED) Recruiting
  2024-513412-10-00 9 2022-05-11 Anaplastic Large Cell Lymphoma (ALCL)
• A Phase 1 First-in-Human Study of the Safety and Effects of VIR-5818 Alone or with Pembrolizumab in Participants with Advanced or Metastatic … Recruiting
  2024-516010-38-00 1 2022-04-25 Participants with Locally Advanced or Metastatic HER2-Expressing Cance
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib … Recruiting
  2022-503068-34-00 4 2022-04-06 Metastatic Gastrointestinal Stromal Tumor
• A phase I study of the mesothelin x cd47 antibody NI-1801, as single agent and in combination with anti-pd-1 antibody, or with paclitaxel al … Recruiting
  2024-517752-35-00 1 2022-04-04 Advanced, metastatic, or recurrent solid mesothelin-expressing maligna
• A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1) Recruiting
  2024-511793-71-00 7 2022-02-28 Advanced ROS1-positive NSCLC and other advanced ROS1-positive solid tu
• HTLP-onco-adult - A phase I/II Study evaluating the safety and the efficacy of Human T Lymphoid Progenitor (HTLP) injection to accelerate im … Recruiting
  2024-516104-42-00 1 2022-02-17 hematologic malignancies ; acute myeloid leukemias
• Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i … Recruiting
  2023-504166-37-00 4 2022-02-01 Advanced ovarian, tubal or peritoneal cancer.
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim … Recruiting
  2024-510690-16-00 5 2022-01-31 Relapsed/refractory follicular lymphoma
• Study evaluating the interest of imatinib treatment maintenance or interruption after at least 10 years of treatment in patients with locall … Recruiting
  2024-512631-77-00 4 2021-12-20 locally advanced or metastatic Gastrointestinal Stromal Tumors
• STUDY TO ASSESS THE SCHEMAS OF RETREATMENT WITH LUTATHERA® IN PATIENTS WITH NEW PROGRESSION OF INTESTINAL WELL-DIFFERENTIATED NEUROENDOCRINE … Recruiting
  2024-511001-28-00 4 2021-12-13 Neuroendocrine tumor
• Short-term Pre-OPerative Durvalumab (MEDI 4736) in early small triple negative breast cancer patients (POP-Durva) Recruiting
  2024-512082-14-00 4 2021-12-06 Untreated small triple negative breast cancer

Showing 433–456 of 961 trials